Project
As clinical trials in HIV prevention grow in complexity, advocacy for future trial design is more important than ever
Global rates of new infections remain high, even as the options for proven prevention increase. Trials to test new HIV prevention methods continue to be imperative, to ensure that communities in need of prevention will be able to find choices that work for them.
As daily and long-acting PrEP products roll out, innovative trial design is a focus and challenge for the field. Advocates and communities must play a central role in shaping future trial design. Their input is essential for both community acceptance of clinical trials and for trial results that advance the field. As trial designs grow more complex, this need is greater than ever.
Launched in September of 2019, AVAC’s Trial Design Academy convenes HIV prevention advocates from across the globe to confront the technical challenges, engage with researchers, statisticians, product developers and regulators, and help shape the decisions to move the research agenda forward.
The academy is built on the belief that meaningful community engagement is critical. This is why it draws on frameworks like the People’s Research Agenda and the Good Participatory Practice to ensure that trial design and conduct is transparent, inclusive and aligned to community priorities.
For more information contact [email protected].
report
There are more biomedical strategies available for HIV prevention than ever before. At the same time, research is continuing. Trials must be able to test new tools and meet ethical standards by providing participants with the best available prevention package.
webinar
CASPR, BAI, & TAG presented a limited research engagement series discussing foundational concepts in next-generation clinical trial designs. This webinar with Deborah Donnell discussed the rationale for exploring new clinical trial designs for HIV prevention. Dr. Donnell discussed the different trial design approaches currently being pursued and answers questions on what advocates need to know.
report
AVAC’s inaugural Trial Design Academy convened in September 2019. At that meeting, a group of around 20 HIV prevention advocates from across the globe explored technical issues related to trial designs, and engaged with researchers, statisticians and regulators to understand the decisions—which must incorporate input from advocates.